What TRANSCEND-T2D-1 Tells Us About Retatrutide in Type 2 Diabetes
If you have type 2 diabetes and you’ve been watching the retatrutide story unfold, March 2026 was a milestone you probably noticed. Eli Lilly reported topline results from TRANSCEND-T2D-1 — the first Phase 3 retatrutide trial in adults with type 2 diabetes to read out. The numbers are striking. They also raise the next question almost immediately: what do they actually tell us, and what are we still waiting for?
TRANSCEND-T2D-1 is a 537-participant, 40-week, randomized, double-blind, placebo-controlled Phase 3 trial that tested three doses of retatrutide (4 mg, 9 mg, and 12 mg) against placebo in adults with type 2 diabetes. According to Lilly’s March 2026 announcement, retatrutide reduced A1C by 1.7 to 2.0 percentage points across doses, compared with 0.8 percentage points on placebo, and produced a mean 16.8% body-weight reduction at the 12 mg dose — equivalent to about 36.6 lbs.
It is the first retatrutide Phase 3 trial in type 2 diabetes to report — but it is not TRIUMPH-2, the larger and longer trial that will anchor a potential diabetes-plus-obesity label. That distinction matters when interpreting what TRANSCEND-T2D-1 does and does not change.
What TRANSCEND-T2D-1 Is — and What It Isn’t
TRANSCEND-T2D-1 is part of TRANSCEND, Eli Lilly’s Phase 3 program for retatrutide in metabolic indications adjacent to obesity. It is distinct from the TRIUMPH program, which carries the obesity-focused trials.
The trial enrolled 537 adults with type 2 diabetes and randomized them in a 1:1:1:1 ratio to retatrutide 4 mg, retatrutide 9 mg, retatrutide 12 mg, or placebo for 40 weeks of treatment. Both A1C and body weight were measured as efficacy endpoints, with cardiometabolic markers tracked as secondary outcomes.
What TRANSCEND-T2D-1 is not: it is not a head-to-head comparison against tirzepatide, semaglutide, or any other approved diabetes drug. It is not a cardiovascular outcomes trial. And it is not the trial that will, on its own, support a U.S. label for retatrutide in type 2 diabetes. That role is expected to fall to TRIUMPH-2.
The Headline Numbers
Three numbers carried the March 2026 announcement.
A1C reduction. Across the three retatrutide doses, A1C dropped by an average of 1.7 to 2.0 percentage points at 40 weeks, compared with a 0.8 percentage point reduction on placebo. The placebo effect itself is meaningful — participants in modern diabetes trials almost always improve somewhat through closer monitoring and lifestyle counseling — but the placebo-adjusted retatrutide effect was approximately 0.9 to 1.2 percentage points, which is at the high end of what has been reported for incretin-based therapies in this duration.
Body-weight reduction. Participants in the 12 mg arm lost a mean 16.8% of body weight (about 36.6 lbs) at 40 weeks. For context, weight loss in people with type 2 diabetes has historically been smaller than weight loss in people without diabetes on the same incretin-based drug. The 16.8% figure is therefore unusually high for a 40-week trial in this population.
No plateau at 40 weeks. Lilly’s announcement specifically noted that participants on retatrutide had not yet reached a weight-loss plateau by week 40. That observation carries weight because it suggests the trajectory could have continued in a longer-duration trial.
How These A1C Reductions Compare
A 1.7 to 2.0 percentage point A1C reduction is a clinically meaningful number. Most modern diabetes drug trials report A1C reductions in the 1.0 to 1.6 percentage point range over 24 to 52 weeks of treatment.
This is not, however, the same thing as saying retatrutide is more effective at lowering A1C than the existing alternatives. TRANSCEND-T2D-1 was placebo-controlled, not active-comparator. There is no head-to-head data here against tirzepatide or semaglutide. Cross-trial comparisons across different populations, baseline characteristics, and definitions of A1C response are notoriously unreliable, and clinicians know to discount them.
What TRANSCEND-T2D-1 does establish is that retatrutide produces an A1C effect in adults with type 2 diabetes that is in the same weight class as the most effective approved drugs. Direct comparisons against tirzepatide are expected later in the program.
Weight Loss in a Diabetes Population — Why This Number Stood Out
Weight loss on incretin-based drugs has historically been smaller in people with type 2 diabetes than in people without it. The reason is partly biological — insulin resistance, baseline insulin levels, and concurrent diabetes medications all influence weight response — and partly behavioral, since people with diabetes often have more complex food relationships and medication regimens.
Against that backdrop, a 16.8% mean weight reduction at 40 weeks in a type 2 diabetes population is large. Earlier dual-agonist trials in similar populations have reported weight reductions in the 10% to 14% range over comparable timeframes. The 16.8% figure is at or above the upper end of that range — and again, it was achieved without reaching a plateau.
For more on how retatrutide is being discussed in the context of insulin resistance, blood sugar, and broader metabolic health, see our retatrutide and metabolic health page.
Cardiometabolic Markers
Beyond A1C and weight, Lilly reported improvements in several secondary cardiometabolic markers, including non-HDL cholesterol, triglycerides, and systolic blood pressure.
These outcomes are typical of incretin-based therapies that produce significant weight loss — much of the cardiometabolic benefit is downstream of weight reduction itself rather than a direct drug effect. TRANSCEND-T2D-1 was not designed to disentangle weight-mediated effects from drug-specific cardiometabolic effects. That distinction matters more in cardiovascular outcomes trials, which are part of the broader retatrutide program but not the focus of TRANSCEND-T2D-1.
What the Safety Profile Looks Like
The adverse-event profile in TRANSCEND-T2D-1 is consistent with the incretin-based therapy class.
The most common adverse events were gastrointestinal: nausea (in up to 26.5% of retatrutide-treated participants), diarrhea (up to 22.8%), and vomiting (up to 17.6%), occurring primarily during the dose-escalation period. Adverse-event-related discontinuations ranged from 2.2% to 5.1% across retatrutide doses, compared with 0% on placebo.
Lilly also reported dysesthesia — abnormal sensations such as tingling or burning — in 2.3% to 4.5% of retatrutide-treated participants. This is a signal worth tracking across the rest of the Phase 3 program, but at TRANSCEND-T2D-1 enrollment scale and duration it has not changed the overall benefit-risk picture.
For broader background on retatrutide tolerability and the kinds of side effects reported across the trial program, see our retatrutide side effects page and the safety and tolerability research summary.
How TRANSCEND-T2D-1 Differs From TRIUMPH-2
It is easy to read TRANSCEND-T2D-1 as the diabetes Phase 3 result, but it is more accurate to read it as the first of several. TRIUMPH-2 is the trial that will most likely carry a U.S. label in adults with type 2 diabetes and obesity, with results expected later in 2026.
The two trials differ in several important ways. TRIUMPH-2 is approximately 1,400 participants — substantially larger than TRANSCEND-T2D-1’s 537. TRIUMPH-2 runs for 52 weeks of placebo-controlled treatment versus 40 weeks. TRIUMPH-2 also enrolls people with both type 2 diabetes and obesity, whereas TRANSCEND-T2D-1 was diabetes-focused and not weighted for BMI in the same way.
The implication: TRANSCEND-T2D-1 establishes the existence and approximate magnitude of retatrutide’s diabetes effect. TRIUMPH-2 is the trial that will be cited in the label, used for payer negotiations, and most heavily compared with tirzepatide’s SURPASS data.
What This Means for Approval Timing
TRANSCEND-T2D-1 is a positive Phase 3 readout. It does not, by itself, mean retatrutide is approved for any indication. As of May 2026, retatrutide remains investigational and is not commercially available.
What the result does change is the probability picture. A clean Phase 3 readout in type 2 diabetes — particularly one with a 16.8% mean weight reduction and a 1.7 to 2.0 percentage point A1C effect — reduces the perceived risk of a setback in the rest of the program. Detailed TRANSCEND-T2D-1 results are scheduled for presentation at the American Diabetes Association Scientific Sessions in June 2026, with full peer-reviewed publication to follow.
For the latest summary of where retatrutide stands in the FDA review process, see our overview of whether retatrutide is FDA-approved and the running retatrutide approval updates.
Stay Updated
If you’d like to receive a single, plain-English update the moment TRIUMPH-2 or another major retatrutide trial reports, you can join our retatrutide updates list. One email per major milestone — no marketing, no third-party sharing.
Disclaimer
Retatrutide is an investigational medication. It is not approved by the FDA for any indication and is not commercially available. This post is educational and should not be interpreted as medical advice or as a recommendation for any specific treatment. For information about how our content is sourced and reviewed, see our editorial policy and medical review policy.
FAQ SECTION
How much weight did people lose on retatrutide in TRANSCEND-T2D-1?
Participants in the retatrutide 12 mg arm lost a mean 16.8% of body weight at 40 weeks, equivalent to approximately 36.6 lbs. Lower doses produced smaller but still substantial reductions. Importantly, Lilly reported that the weight-loss curve had not plateaued by week 40, suggesting the trajectory could have continued in a longer-duration trial.
Was TRANSCEND-T2D-1 a head-to-head trial against tirzepatide or semaglutide?
No. TRANSCEND-T2D-1 was placebo-controlled, meaning retatrutide was compared against a matching placebo injection rather than against another approved diabetes drug. Direct head-to-head comparisons against tirzepatide are expected later in the retatrutide program. Cross-trial comparisons against existing drugs are unreliable because populations, baseline characteristics, and trial designs differ.
What were the most common side effects in TRANSCEND-T2D-1?
The most common adverse events were gastrointestinal: nausea (up to 26.5%), diarrhea (up to 22.8%), and vomiting (up to 17.6%). These occurred primarily during dose escalation. Adverse-event-related discontinuation rates ranged from 2.2% to 5.1% across retatrutide doses versus 0% on placebo. The pattern is consistent with incretin-based therapies as a class.
When will the full TRANSCEND-T2D-1 paper be published?
Detailed TRANSCEND-T2D-1 results are scheduled for presentation at the American Diabetes Association Scientific Sessions in June 2026, with full peer-reviewed publication expected to follow in a major medical journal. Until then, the publicly available data is the topline announcement Eli Lilly issued in March 2026.
Does TRANSCEND-T2D-1 mean retatrutide is approved for diabetes?
No. TRANSCEND-T2D-1 is a positive Phase 3 readout, but it does not constitute regulatory approval. Retatrutide remains investigational and is not commercially available for any indication. A potential U.S. label in type 2 diabetes is more likely to be carried by TRIUMPH-2, a larger and longer Phase 3 trial expected to report later in 2026.
How many people were in the TRANSCEND-T2D-1 trial?
TRANSCEND-T2D-1 enrolled 537 adults with type 2 diabetes, randomized 1:1:1:1 to retatrutide 4 mg, 9 mg, 12 mg, or placebo. The trial duration was 40 weeks. By comparison, TRIUMPH-2 — the larger Phase 3 retatrutide diabetes trial — enrolls approximately 1,400 participants over 52 weeks.
